Omeros Corporation

Omeros Corporation is a biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. 

Omeros has clinical-stage development programs focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. In addition, Omeros has a diverse group of preclinical programs and two additional platforms: one capable of unlocking new G protein-coupled receptor, or GPCR, drug targets and the other used to generate antibodies.

The Company's marketed drug product OMIDRIA® was launched in the U.S. for use during cataract surgery or intraocular lens, or IOL, replacement. OMIDRIA is the first FDA-approved drug for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis and to reduce postoperative ocular pain and that contains a NSAID for intraocular use.

Company Growth (employees)
Type
Public
HQ
Seattle, US
Founded
1994
Size (employees)
154 (est)-4%
Website
omeros.com
Omeros Corporation was founded in 1994 and is headquartered in Seattle, US

Key People at Omeros Corporation

Gregory A. Demopulos

Gregory A. Demopulos

Chairman and Chief Executive Officer
Wayne Wager

Wayne Wager

Director
Timothy M. Duffy

Timothy M. Duffy

Vice President, Business Development

Omeros Corporation Office Locations

Omeros Corporation has an office in Seattle
Seattle, US (HQ)
201 Elliott Ave

Omeros Corporation Data and Metrics

Omeros Corporation Financial Metrics

Omeros Corporation's revenue was reported to be $12.3 m in Q1, 2017
USD

Revenue (Q1, 2017)

12.3 m

Gross profit (Q1, 2017)

12 m

Gross profit margin (Q1, 2017), %

98%

Net income (Q1, 2017)

(15.1 m)

EBIT (Q1, 2017)

(12.7 m)

Market capitalization (17-Aug-2017)

990 m

Cash (31-Mar-2017)

1.3 m
Omeros Corporation's current market capitalization is $990 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.6 m539 k13.5 m41.6 m

Revenue growth, %

(66%)2406%208%

Cost of goods sold

1 m1.4 m

Gross profit

12.5 m40.2 m

Gross profit Margin, %

92%97%

Operating expense total

52.1 m70.5 m84.7 m95.9 m

EBIT

(50.5 m)(70 m)(71.2 m)(54.3 m)

EBIT margin, %

(3157%)(12988%)(527%)(130%)

Interest expense

(2.4 m)(3.5 m)(3.6 m)(7.8 m)

Net Income

(39.8 m)(73.7 m)(75.1 m)(66.7 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

45 k214 k388 k3.2 m3.3 m7.4 m10 m11.3 m12.3 m

Cost of goods sold

11 k365 k248 k327 k327 k378 k271 k

Gross profit

377 k2.8 m3 m7.1 m9.7 m10.9 m12 m

Gross profit Margin, %

97%89%92%96%97%97%98%

R&D expense

12.4 m11.8 m9.3 m10.9 m13.3 m15.4 m10.2 m12.5 m12.2 m

General and administrative expense

4.9 m5.6 m9 m7.9 m9 m11.1 m10.4 m10.5 m12.5 m

Operating expense total

17.3 m17.3 m18.3 m18.8 m22.3 m26.5 m20.6 m22.9 m24.7 m

EBIT

(17.2 m)(17.1 m)(17.9 m)(16 m)(19.3 m)(19.5 m)(10.9 m)(12 m)(12.7 m)

EBIT margin, %

(38260%)(8006%)(4621%)(501%)(592%)(262%)(109%)(107%)(104%)

Interest expense

(939 k)(944 k)(957 k)(937 k)(871 k)(1.4 m)(1.9 m)(2.1 m)(2.7 m)

Net Income

(34.6 m)(53 m)(18.7 m)(35.3 m)(55.3 m)(20.5 m)(33.2 m)(47.1 m)(15.1 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

1.4 m354 k1.4 m2.2 m

Accounts Receivable

14.6 m

Inventories

337 k472 k1.1 m

Current Assets

14.8 m9.2 m37.1 m60.3 m

PP&E

939 k782 k951 k1.2 m

Total Assets

16.5 m11.1 m49 m67.3 m

Accounts Payable

2.3 m4.9 m6.4 m2.5 m

Current Liabilities

11.9 m18.4 m16.3 m16.1 m

Additional Paid-in Capital

235.7 m285.1 m376.5 m432 m

Retained Earnings

(254.4 m)(328 m)(403.1 m)(469.9 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

1.5 m750 k1.4 m2.6 m601 k978 k4.6 m10.3 m1.3 m

Inventories

566 k633 k445 k2 m1.8 m1.4 m960 k

Current Assets

39 m23.4 m73.1 m56.7 m39.5 m24.3 m34.1 m60.6 m51.4 m

PP&E

907 k846 k727 k789 k808 k898 k1.3 m1.2 m1.2 m

Total Assets

41 m25.3 m74.9 m58.6 m41.4 m36 m46.1 m72.8 m58.4 m

Accounts Payable

5.1 m4.2 m4.6 m4 m4.6 m5.3 m5.4 m4 m2.4 m

Current Liabilities

12.2 m14.4 m20.1 m20.1 m22.3 m17.5 m16.1 m16.1 m17 m

Additional Paid-in Capital

278.1 m280.4 m368.2 m370.9 m373.9 m382.5 m386.9 m427.1 m436.4 m

Retained Earnings

(289 m)(307.3 m)(346.7 m)(363.4 m)(383.3 m)(423.7 m)(436.3 m)(450.3 m)(485 m)

Total Equity

7.9 m(9 m)

Financial Leverage

7.4 x-4.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(39.8 m)(73.7 m)(75.1 m)(66.7 m)

Depreciation and Amortization

302 k326 k209 k300 k

Inventories

96 k(656 k)

Accounts Payable

4.2 m(319 k)

Cash From Operating Activities

(29.7 m)(58 m)(65.2 m)(51.5 m)

Purchases of PP&E

(204 k)

Cash From Investing Activities

7.9 m6.2 m(20.6 m)(16.3 m)

Long-term Borrowings

(1.5 m)

Cash From Financing Activities

21.7 m50.9 m86.8 m68.7 m

Interest Paid

1.7 m2.7 m4.2 m5.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(34.6 m)(53 m)(18.7 m)(35.3 m)(55.3 m)(20.5 m)(33.2 m)(47.1 m)(15.1 m)

Depreciation and Amortization

164 k246 k55 k107 k161 k53 k122 k211 k

Inventories

(1.5 m)(1.3 m)(924 k)960 k

Accounts Payable

4.3 m3.9 m1.3 m(268 k)(303 k)2.4 m

Cash From Operating Activities

(26.4 m)(42.4 m)(17.5 m)(34 m)(48.6 m)(16.6 m)(29.4 m)(40.6 m)

Cash From Investing Activities

(23.2 m)(8.3 m)(62.1 m)(42.5 m)(28.1 m)14.6 m10.2 m(10.3 m)

Short-term Borrowings

(4.7 m)

Long-term Borrowings

(1.5 m)(1.5 m)(2.3 m)(34 k)(62 k)

Cash From Financing Activities

49.8 m50 m80.7 m78.7 m76.9 m1.6 m22.4 m59.9 m

Interest Paid

1.2 m1.9 m745 k1.5 m2.1 m776 k2 m3.6 m
USDY, 2017

Revenue/Employee

75.7 k

Omeros Corporation Market Value History

Traffic Overview of Omeros Corporation

Omeros Corporation Online and Social Media Presence

Omeros Corporation Company Life and Culture

You may also be interested in